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Aims: Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) was lower in the general population with
metabolic syndrome (MetS). The aim of this study was to evaluate the relationship between MetS and fasting serum
NT-proBNP concentration in elderly persons.
Methods: Fasting blood samples were obtained from 84 elderly volunteers aged 65 years or older. MetS and its
components were defined using diagnostic criteria from the International Diabetes Federation.
Results: Thirty-eight elderly persons (45.2%) had MetS. Fasting NT-proBNP level was negatively correlated with MetS
among elderly patients (p = 0.001). Univariate linear regression analysis showed that age (r = 0.338; p = 0.002) was
positively correlated with fasting serum log-NT-proBNP levels, while height (r = −0.253; p = 0.020), body weight
(r = −0.238; p = 0.029), waist circumference (r = −0.270; p = 0.013), body fat mass (r = −0.356; p = 0.002) and
triglyceride (r = −0.291; p = 0.007) were negatively correlated with fasting serum log-NT-proBNP levels among the
elderly persons. Multivariate forward stepwise linear regression analysis of the significant variables showed that age
(R2 change = 0.114, p = 0.011), triglyceride (R2 change = 0.118, p < 0.001), body fat mass (R2 change = 0.084,
p < 0.001), and height (R2 change = 0.101, p < 0.001) were the independent predictor of fasting serum
log-NT-proBNP levels in elderly persons.
Conclusions: NT-proBNP level is significantly reduced in elderly persons affected by MetS, and is significantly
positively related to age, while negatively related to triglyceride, body fat mass, height in these subjects.
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The heart secretes two natriuretic peptides, atrial natri-
uretic peptides (ANP) and B-type natriuretic peptides
(BNP). They are widely known as body homeostasis reg-
ulators that oppose volume expansion [1]. BNP and its
N-terminal counterpart, N-terminal pro-B-type natri-
uretic peptide (NT-proBNP), are cardiac biomarkers that
have been established for the assessment of congestive
heart failure [2,3]. Recent studies also suggested natri-
uretic peptides are potent lipolytic agents that act in adi-
pose tissue [4,5]. Low levels of NT-proBNP might lead* Correspondence: gee.lily@msa.hinet.net
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unless otherwise stated.to reduced lipolysis and excessive weight gain, which
may be one of the biological alterations that contribute
to the development of metabolic syndrome in the gen-
eral population (MetS) [6,7].
In old age, fat is redistributed from subcutaneous to
intra-abdominal visceral depots as well as other ectopic
sites, including bone marrow, muscle and the liver.
These changes are associated with increased risk of
MetS [8]. MetS increased all-cause and cardiovascular
disease mortality in a cohort study of Chinese aged
50 years or older [9]. There is no study about the associ-
ation between serum NT-proBNP levels and MetS in
elderly persons. The aim of this study was to investigate
the relationship between the fasting serum NT-proBNP
level and MetS among elderly persons.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Participants
Between October 2009 and May 2010, one hundred eld-
erly volunteers aged 65 years or older at a medical center
in Hualien, eastern Taiwan were enrolled into this study.
The Protection of the Human Subjects Institutional Re-
view Board of Tzu-Chi University and Hospital approved
this study. Patients were excluded if they had any acute in-
fection (n = 2), acute myocardial infarction (n = 1), heart
failure (n = 5), serum creatinine ≥ 1.2 mg/dl at the time of
blood sampling (n = 7) or if they refused to provide in-
formed consent for the study (n = 1). Heart failure defined
by the American College of Cardiology Foundation and
the American Heart Association 2005 Guidelines. Heart
failure is a complex clinical syndrome that can result from
any structural or functional cardiac disorder that impairs
the ability of the ventricle to fill with or eject blood [10].
Total about eighty-four elderly volunteers (28 males and
56 females) were included in this study.
Anthropometric analysis
Body weight was measured to the nearest half-kilogram
with patients wearing light clothing and without shoes.
Height was measured to the nearest 0.5 cm. Waist cir-
cumference was measured by tape around patient’s waist
from the point between patient’s lowest ribs and patient’s
hip bones by placing patient’s hands on patient’s hips.
The body mass index (BMI) was calculated as weight
(kilograms) divided by height squared (meters). Bioimpe-
dance measurements of fat mass were performed at the
bedside according to the standard tetrapolar whole body
(hand-foot) technique, using a single-frequency (50-kHz)
analyzer (Biodynamic-450, Biodynamics Corporation,
Seattle, USA). Measurements were carried out by the
same operator. Fat mass was collected and analyzed by
specific formulae supplied by the manufacturer. [11,12].
2D echocardiographic examination
The 2D echocardiographic recordings were obtained in
all patients using commercially available machines. Ejec-
tion fraction was calculated by a modification of the
method of Quinones et al. [13]. The left ventricular (LV)
mass index was calculated as a ratio of LV mass to body
surface area. Transmitral flow velocity curves were re-
corded to measure peak early diastolic (E) and late dia-
stolic (A) velocities. There are three components of the
tissue Doppler profile that are routinely measured: the
systolic myocardial velocity (S’); the early diastolic myo-
cardial velocity (E’); and the late diastolic myocardial vel-
ocity (A’) as previously described [14].
Biochemical investigations
Fasting blood samples of approximately 5 ml for measur-
ing complete blood count (Sysmex K-1000, Bohemia,NY, USA) and other factors were immediately centrifuged
at 3000 g for 10 min. Serum levels of blood urea nitrogen
(BUN), creatinine (Cre), fasting glucose, total cholesterol
(TCH), triglyceride (TG), high-density lipoprotein cho-
lesterol (HDL-cholesterol), and low-density lipoprotein
cholesterol (LDL-cholesterol) were measured using an
autoanalyzer (COBAS Integra 800, Roche Diagnostics,
Basel, Switzerland). Blood samples were assayed for NT-
proBNP by electrochemiluminescence immunoassay on
the Elecsys 2010 Immunoanalyzer (Roche Diagnostics,
Indianapolis, IN, USA).
Metabolic syndrome and its components
The prevalence of MetS was defined using the Inter-
national Diabetes Federation definition [15]. People were
classified as having MetS if they had central (abdominal)
obesity with a waist circumference ≥ 90 cm (men) or ≥
80 cm (women) (Chinese criteria), and matched two or
more of the following criteria: fasting serum glucose of
110 mg/dl or more, triglycerides of 150 mg/dl or higher,
HDL-cholesterol level less than 40 mg/dl in men or less
than 50 mg/dl in women, or blood pressure of 130/
85 mmHg or higher. The use of antihypertensive medica-
tion was considered as indicative of high blood pressure in
this analysis. Type 2 diabetes was determined according to
World Health Organization criteria [16]. A person was
regarded as diabetic if the fasting plasma glucose was ei-
ther 126 mg/dl or more, or if the 2 h glucose during an
oral glucose tolerance test was 200 mg/dl or more, or if
he/she was using diabetes medication (oral or insulin).
Statistical analysis
Data are expressed as means ± standard deviation (SD)
and were tested for normal distribution by Kolmogorov-
Smirnov test. Categorical variables were analyzed by the
Chi-square test. Comparisons between patients were per-
formed using the Student’s independent t test (two-tailed)
for normally distributed data or the Mann–Whitney U test
for parameters that presented with non-normal distribu-
tion (NT-proBNP). Because the NT-proBNP was non-
normal distribution, we used log-NT-proBNP (logarithm
of NT-proBNP to base 10) and noted log-NT-proBNP was
normal distribution. The significance of differences of NT-
proBNP between numbers of metabolic syndrome criteria
was analyzed by the Kruskal-Wallis analysis of variance
(AVONA) test. Clinical variables that correlated with
serum log-NT-proBNP levels in elderly persons were eval-
uated by univariate linear regression analyses. Variables
that were significantly associated with log-NT-proBNP in
elderly persons were tested for independency in multivari-
ate forward stepwise regression analysis. Data were ana-
lyzed using SPSS for Windows (version 13.0; SPSS Inc.,
Chicago, IL, USA). A p-value of less than 0.05 was consid-
ered statistically significant.
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The clinical, echocardiographic recordings and laboratory
characteristics of the elderly persons are presented in
Table 1 and Table 2. Medical histories included: diabetes
(n = 30; 35.7%), and hypertension (n = 68; 80.9%). The use
of drugs included: angiotensin receptor blocker (ARB; n =
40; 47.4%), angiotensin-converting enzyme inhibitor
(ACEI; n = 16; 19.1%), calcium channel blocker (CCB; n =
46; 54.8%), β-blocker (n = 38; 45.2%), statin (n = 20;
23.8%), fibrate (n = 10; 11.9%), sulfonylurea (n = 8; 9.5%),
and metformin (n = 18; 21.4%). Thirty-eight patients
(45.2%) had MetS, whereas 46 patients (54.8%) did not.
Elderly persons who had MetS had lower serum fasting
NT-proBNP levels than those without MetS (p = 0.001).
NT-proBNP levels did not differ statistically by gender dis-
tribution, diabetes, hypertension, ARB, ACEI, CCB, β-
blocker, statin, fibrate, sulfonylurea, or metformin drugs
used.
Fasting serum NT-proBNP levels in different metabolic
syndrome diagnostic criteria are presented in Figure 1.
There was a tendency for decreased fasting NT-proBNP
levels as the number of diagnostic criteria for metabolic
syndrome in patients increased. A statistically significant
difference between the number of metabolic syndrome
criteria and serum NT-proBNP levels in elderly persons
(p = 0.030) was established.
The univariate linear analysis of fasting serum log-NT-
proBNP levels in elderly persons is presented in Table 3.
Ages (r = 0.338; p = 0.002) was positively correlated with
fasting serum log-NT-proBNP levels, while height
(r = −0.253; p = 0.020), body weight (r = −0.238; p =Table 1 Clinical and analytical characteristics of 84 elderly pe
Item Parameter
Anthropometric findings Height (cm) 156
Body weight (kg) 67.5
Body mass index (kg/m2) 27.4
DBP (mmHg) 72.5
Echocardiographic finding LV ejection fraction (%) 66.5
Mitral E (cm/s) 51.8
Mitral E/A ratio 0.67
A’ (cm/s) 10.4
S’ (cm/s) 7.90
Biochemical findings Triglyceride (mg/dl) 142




Data are expressed as means ± standard deviations or proportion.
SBP, systolic blood pressure; DBP, diastolic blood pressure; LV, left ventricular; A’, la
S’, systolic myocardial velocity; E/E’, ratio of peak mitral E wave velocity to peak ear
imaging; HDL-cholesterol, high-density lipoprotein cholesterol; LDL-cholesterol, low
cells; NT-proBNP, N-terminal pro-B-type natriuretic peptide.0.029), waist circumference (r = −0.270; p = 0.013),
body fat mass (r = −0.356; p = 0.002) and triglyceride
(r = −0.291; p = 0.007) were negatively correlated with
fasting serum log-NT-proBNP levels among the elderly
persons (Table 3).
Multivariate forward stepwise linear regression analysis
of the variables that were significantly associated with fast-
ing serum log-NT-proBNP levels among elderly persons
showed that age (β = 0.242, R2 change = 0.114, p = 0.011),
triglyceride (β = −0.392, R2 change = 0.118, p < 0.001),
body fat mass (β = −0.398, R2 change = 0.084, p < 0.001),
and height (β = −0.362, R2 change = 0.101, p < 0.001) were
the independent predictor of fasting serum log-NT-pro-
BNP levels (Table 4).
Discussion
The results of our study showed that the fasting NT-
proBNP level was negatively associated with MetS in
elderly persons, and that age, triglyceride, body fat mass
and height were independent predictors of fasting serum
NT-proBNP levels.
In elderly people disorders occur that are closely re-
lated to the ageing process. They include symptoms
from the cardiovascular system, such as elevated systolic
blood pressure, pulse pressure, increased mass of the left
ventricle and more frequent ischemic heart disease, as
well as cardiac arrhythmias, and particularly atrial fibril-
lation [17]. As compared to normal volunteers echocar-
diographic data at Aizawa et al. [14 our study noted the
E/A ratio and E’ were lower, and the LV mass index was
higher in elderly persns.rsons
Parameter
.89 ± 6.00 Waist circumference (cm) 96.02 ± 9.68
3 ± 9.86 Body fat mass (%) 37.31 ± 7.14
0 ± 3.53 Age (year) 73.31 ± 4.66
3 ± 7.36 SBP (mmHg) 131.96 ± 9.86
9 ± 13.47 LV mass index (g/m2) 103.37 ± 26.64
5 ± 17.11 Mitral A (cm/s) 80.89 ± 20.20
± 0.28 E’ (cm/s) 5.87 ± 1.98
8 ± 2.67 E/E’ ratio 9.73 ± 5.86
± 1.57
.30 ± 82.39 Total cholesterol (mg/dl) 192.60 ± 37.74
.16 ± 29.83 HDL-cholesterol (mg/dl) 49.69 ± 13.34
.58 ± 35.26 Creatinine (mg/dl) 0.87 ± 0.17
1 ± 4.77 WBC (x1000/ul) 6.85 ± 1.69
4 ± 1.84 NT-proBNP (pg/ml) 251.26 ± 282.69
te diastolic myocardial velocity; E’, early diastolic myocardial velocity;
ly diastolic myocardial velocity at septal position recorded by tissue Doppler
-density lipoprotein cholesterol; BUN, blood urea nitrogen; WBC, white blood
Table 2 Clinical characteristics and fasting serum
N-terminal pro-B-type natriuretic peptide levels of
84 elderly persons
Characteristic Number (%) NT-proBNP
(pg/ml)
P value
Gender Male 28 (33.3) 173.50 ± 227.45 0.284
Female 56 (66.7) 290.14 ± 302.88
Diabetes No 54 (64.3) 218.80 ± 275.99 0.636
Yes 30 (35.7) 269.30 ± 289.92
Hypertension No 16 (19.1) 336.25 ± 370.62 0.223
Yes 68 (80.9) 231.26 ± 260.74
Metabolic syndrome No 46 (54.8) 384.87 ± 342.22 0.001*
Yes 38 (45.2) 89.53 ± 55.88
ACE inhibitor No 68 (80.9) 236.53 ± 281.99 0.748
Yes 16 (19.1) 313.88 ± 296.03
ARB No 40 (47.6) 306.30 ± 315.87 0.251
Yes 44 (52.4) 201.23 ± 245.44
β-blocker No 46 (54.8) 262.09 ± 310.44 0.622
Yes 38 (45.2) 238.16 ± 252.79
CCB No 38 (45.2) 326.26 ± 325.47 0.100
Yes 46 (54.8) 189.30 ± 231.05
Statin No 64 (76.2) 276.50 ± 306.19 0.506
Yes 20 (23.8) 170.50 ± 177.76
Fibrate No 74 (88.1) 264.46 ± 296.72 0.938
Yes 10 (11.9) 168.40 ± 130.17
Sulfonylurea No 76 (90.5) 265.50 ± 293.33 0.780
Yes 8 (9.5) 116.00 ± 62.79
Metformin No 66 (78.6) 249.15 ± 268.06 0.690
Yes 18 (21.4) 259.00 ± 349.32
Data are expressed as means ± standard deviations.
*P < 0.05 was considered statistically significant after Mann–Whitney U test.
NT-pro-BNP, N-terminal pro-B-type natriuretic peptide; ARB, angiotensin-
receptor blocker; ACE, angiotensin-converting enzyme; CCB,
calcium-channel blocker.
Figure 1 Fasting serum N-terminal pro-B-type natriuretic
peptide levels in different metabolic syndrome diagnostic
criteria among the 84 elderly persons. Data was analyzed by the
Kruskal-Wallis analysis of variance (AVONA) test.
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that has been associated with increased risk of cardio-
vascular disease, diabetes, and mortality as well as other
adverse health outcomes [15]. Aging is characterized by
body fat redistribution with increased visceral fat and
relative loss of subcutaneous fat, especially in the periph-
ery. The impaired capacity of fat tissue to store lipids as-
sociated with aging may be responsible for increased
systemic free fatty acid exposure, leading to ectopic fat
deposition, lipotoxicity and metabolic disease [8]. An-
thropometric changes with an increase in fat mass with
a parallel decline in fat free mass, environmental
changes such as dietary habit changes and reduced phys-
ical activity, neurohormonal variations which may have
an opposing effect on insulin, and an increase in oxida-
tive stress in the elderly induce insulin resistance andare associated with impaired glucose handling, mainly
through the decline of insulin action in the elderly [18].
The MetS is associated with the incidence of diabetes,
and the synergy between MetS and diabetes is an im-
portant risk factor for all-cause mortality in elderly sub-
jects [19]. MetS in an elderly population is a proven risk
factor for all-cause and cardiovascular disease mortality
[9]. The prevalence of MetS in the United States is
43.5% and 42.0% for participants aged 60 through
69 years and aged at least 70 years, respectively [20].
Our study noted the overall prevalence of MetS is 45.2%
in the elderly and the prevalence of MetS was 42.9%
(12/28) in men and 46.4% (26/56) in women.
The renin-angiotensin-aldosterone system is activated in
obese patients and angiotensin II acting as a ‘growth fac-
tor’ for adipose tissue growth and development [4]. BNP
binds its common receptor, guanylyl cyclase-A (GC-A),
which leads to biological actions through a cyclic guano-
sine monophosphate (cGMP)-dependent pathway and has
an inhibition effect of the renin–angiotensin–aldosterone
axis [2]. So, low levels of natriuretic peptide may activate
the renin-angiotensin-aldosterone system, which may con-
tribute to the development of obesity. In normal subjects,
natriuretic peptide may affect the homoeostasis of glucose
and lipid metabolism, partly through the reduction in adi-
pogenesis, as well as the increased release and more
efficient consumption of non-esterified fatty acids by per-
ipheral tissues [21]. It can be speculated that low levels of
natriuretic peptide may lead to reduced lipolysis and ex-
cessive weight gain, which may be one of the biological al-
terations that contribute to the development of obesity
[5]. BNP through a cGMP-dependent pathway can pro-
mote muscle mitochondrial biogenesis and fat oxidation,
as to prevent obesity and glucose intolerance in mice [22].
Some studies did not find an association between serum
NT-proBNP concentrations and MetS [23,24]. However,
Table 3 Correlation of logarithm of fasting serum
N-terminal pro-B-type natriuretic peptide levels and
clinical variables by univariate linear regression analyses
among the 84 elderly persons
Items Beta P value
Age (year) 0.338 0.002*
Height (cm) −0.253 0.020*
Body weight (kg) −0.238 0.029*
Waist circumference (cm) −0.270 0.013*
Body mass index (BMI; kg/m2) −0.140 0.205
Body fat mass (%) −0.326 0.002*
White blood cell (x1000/ul) −0.070 0.544
Hemoglobin (g/dl) −0.107 0.144
Total cholesterol (mg/dl) −0.016 0.888
Triglyceride (mg/dl) −0.291 0.007*
HDL-C (mg/dl) 0.188 0.087
LDL-C (mg/dl) 0.013 0.908
Fasting glucose (mg/dl) 0.210 0.056
Blood urea nitrogen (mg/dl) 0.163 0.144
Creatinine (mg/dl) −0.133 0.227
Systolic pressure (mmHg) 0.103 0.351
Diastolic pressure (mmHg) −0.110 0.317
*P < 0.05 was considered statistically significant after univariate linear analyses.
HDL-cholesterol, high-density lipoprotein cholesterol; LDL-cholesterol,
low-density lipoprotein cholesterol.
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general population with MetS [6,7]. Recent study on eld-
erly population from Poland noted obese patients had sig-
nificantly more frequently NT-proBNP values < 400 pg/ml
(73.0%) and less frequently NT-proBNP values > 2000 pg/
ml (2.8%) [25]. Our study also noted that elderly persons
with MetS had lower fasting serum NT-proBNP levels.
Moreover, our study also noted a tendency for decreasing
fasting serum NT-proBNP levels as the number of diag-
nostic criteria for metabolic syndrome in elderly persons
increased.
NT-proBNP values were substantially higher in women
compared to men at every age, and levels increased withTable 4 Multivariate stepwise linear regression analysis
of age, height, body weight, waist circumference, body
fat mass, and triglyceride: correlation to logarithm of
fasting serum N-terminal pro-B-type natriuretic peptide
levels among 84 elderly persons
Items Beta R square R square change P value
Age (year) 0.242 0.114 0.114 0.011*
Triglyceride (mg/dl) −0.392 0.232 0.118 < 0.001*
Body fat mass (%) −0.398 0.316 0.084 < 0.001*
Height (cm) −0.362 0.417 0.101 < 0.001*
*P <0.05 was considered statistically significant after multivariate stepwise
linear regression analyses.increasing age for both genders in healthy individuals
from the Framingham Heart Study Generation 3 cohort
study [26]. This study also noted upper reference limit
for NT-proBNP implied is more than 2-fold higher in
women than men [26]. Our result also showed that age
was positively correlated with fasting serum log-NT-
proBNP levels and nearly 2-fold higher in women than
men among the elderly persons. Although gender differ-
ences in circulating natriuretic peptides have been previ-
ously reported, the underlying mechanisms remain
unclear [27]. In symptomatic left ventricular systolic
heart failure patients a higher BMI is associated with de-
creased NT-proBNP levels [28]. Our study noted that
height and body weight were negatively correlated with
fasting serum log-NT-proBNP levels in elder persons,
but did not differ statistically by BMI in this study.
Plasma NT-proBNP was inversely associated with vis-
ceral adipose tissue volumes measured by multidetector
computed tomography in a study of 1,873 community-
based individuals [29]. However, another study noted
NT-proBNP was inversely associated with hematocrit
and hepatic steatosis, while no association was found
with waist circumference and skinfold fat measurement
in the elderly [30]. Serum NT-proBNP was inversely re-
lated to triglyceride [6,24]. Our study also showed that
waist circumference, body fat mass, and triglyceride were
negatively correlated with fasting serum log-NT-proBNP
levels among the elderly persons. Multivariate forward
stepwise linear regression analysis of significant variables
showed that age, triglyceride, body fat mass, and height
were waist circumference was the independent predictor
of fasting serum log-NT-proBNP levels in our study.
Pharmacological interventions have been shown to in-
fluence serum NT-proBNP in humans. The use of valsar-
tan reduces plasma concentrations of NT-proBNP in
post–myocardial infarction and congestive heart failure
patients [31]. After 8 weeks of treatment with losartan a
significant decrease was noted in the levels of NT-proBNP
in patients after acute myocardial infarction [32]. NT-
proBNP was significantly reduced after six months of
treatment with enalapril or carvedilol combined with enal-
april treatment in stable systolic heart failure patients. In
contrast, no change was observed in the carvedilol group
[33]. Atorvastatin treatment reduced NT-proBNP levels in
heart failure patients [34]. Our results did not show a rela-
tionship between statins or other drugs (angiotensin re-
ceptor blocker, angiotensin-converting enzyme inhibitor,
calcium channel blocker, or β-blocker) and serum NT-
proBNP among elderly persons. Further studies are re-
quired to elucidate the relationship between medication
and NT-proBNP in elderly persons.
Our study has some limitations. First, the number of
patients enrolled was small and there was weak statis-
tical power in terms of the small number of patients.
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proBNP, have been shown a high prognostic value in total
mortality, cardiovascular mortality in the elderly popula-
tion and is independent predictor of all-cause mortality in
patients with acute heart failure at 30 days and 1 year after
emergency department in elderly persons [35,36]. There-
fore, our findings should be investigated in long-term pro-
spective studies before a causal relationship between
serum NT-proBNP and MetS in elderly persons can be
established. It should also be noted that BNP can enhance
adiponectin production by human adipocytes in vitro and
even in patients with heart failure [37]. Serum adiponectin
values were found to correlate inversely with the presence
of MetS [38]. Adiponectin is independently associated
with NT-proBNP in the general population [39] and in
elderly coronary artery disease patients [40]. Additional
studies are required to ascertain whether the serum con-
centration of adiponectin is associated with NT-proBNP
in elderly persons.
Conclusion
Low levels of NT-proBNP might lead to reduced lipolysis
and excessive weight gain, which may be one of the bio-
logical alterations that contribute to the development of
MetS. The present study shows a negative association be-
tween circulating fasting NT-proBNP and MetS among
elderly persons. Age, triglyceride, body fat mass and height
were independent predictor of the serum log-NT-proBNP
level among elderly persons.
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